Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases.

Matza LS, Cong Z, Chung K, Stopeck A, Tonkin K, Brown J, Braun A, Van Brunt K, McDaniel K.

Patient Prefer Adherence. 2013 Aug 29;7:855-65. doi: 10.2147/PPA.S44947. eCollection 2013.

2.

Health state utilities for skeletal-related events secondary to bone metastases.

Matza LS, Chung K, Van Brunt K, Brazier JE, Braun A, Currie B, Palsgrove A, Davies E, Body JJ.

Eur J Health Econ. 2014 Jan;15(1):7-18. doi: 10.1007/s10198-012-0443-2. Epub 2013 Jan 25.

3.

Health state utilities associated with attributes of treatments for hepatitis C.

Matza LS, Sapra SJ, Dillon JF, Kalsekar A, Davies EW, Devine MK, Jordan JB, Landrian AS, Feeny DH.

Eur J Health Econ. 2015 Dec;16(9):1005-18. doi: 10.1007/s10198-014-0649-6. Epub 2014 Dec 7.

4.

Bisphosphonates for breast cancer.

Pavlakis N, Schmidt R, Stockler M.

Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003474. Review. Update in: Cochrane Database Syst Rev. 2012;2:CD003474.

PMID:
16034900
5.

Acute and chronic impact of cardiovascular events on health state utilities.

Matza LS, Stewart KD, Gandra SR, Delio PR, Fenster BE, Davies EW, Jordan JB, Lothgren M, Feeny DH.

BMC Health Serv Res. 2015 Apr 22;15:173. doi: 10.1186/s12913-015-0772-9.

6.

Risks associated with antiretroviral treatment for human immunodeficiency virus (HIV): qualitative analysis of social media data and health state utility valuation.

Matza LS, Chung KC, Kim KJ, Paulus TM, Davies EW, Stewart KD, McComsey GA, Fordyce MW.

Qual Life Res. 2017 Jul;26(7):1785-1798. doi: 10.1007/s11136-017-1519-3. Epub 2017 Mar 24.

PMID:
28341926
7.

Utilities and disutilities for type 2 diabetes treatment-related attributes.

Matza LS, Boye KS, Yurgin N, Brewster-Jordan J, Mannix S, Shorr JM, Barber BL.

Qual Life Res. 2007 Sep;16(7):1251-65. Epub 2007 Jul 19.

PMID:
17638121
8.

Health state utilities associated with major clinical events in the context of secondary hyperparathyroidism and chronic kidney disease requiring dialysis.

Davies EW, Matza LS, Worth G, Feeny DH, Kostelec J, Soroka S, Mendelssohn D, McFarlane P, Belozeroff V.

Health Qual Life Outcomes. 2015 Jun 30;13:90. doi: 10.1186/s12955-015-0266-9.

9.

Health state utilities associated with adult attention-deficit/hyperactivity disorder.

Matza LS, Devine MK, Haynes VS, Davies EW, Kostelec JM, Televantou F, Jordan JB.

Patient Prefer Adherence. 2014 Jul 17;8:997-1006. doi: 10.2147/PPA.S62776. eCollection 2014.

10.

Quality of life related to oral versus subcutaneous iron chelation: a time trade-off study.

Osborne RH, De Abreu Lourenço R, Dalton A, Houltram J, Dowton D, Joshua DE, Lindeman R, Ho PJ.

Value Health. 2007 Nov-Dec;10(6):451-6.

11.

Patient management, and time and health care resource utilization associated with the use of intravenous bisphosphonates for patients with metastatic bone disease: a Delphi study.

Xie F, Hopkins R, Burke N, Tarride JE, Goeree R.

Hosp Pract (1995). 2012 Apr;40(2):131-7. doi: 10.3810/hp.2012.04.978.

PMID:
22615087
12.

A valuation of infusion therapy to preserve islet function in type 1 diabetes.

Lloyd A, Swinburn P, Boye KS, Curtis B, Sarpong E, Goldsmith K, Bode B, Aronoff S.

Value Health. 2010 Aug;13(5):636-42. doi: 10.1111/j.1524-4733.2010.00705.x.

13.

Impact of caregiver and parenting status on time trade-off and standard gamble utility scores for health state descriptions.

Matza LS, Boye KS, Feeny DH, Johnston JA, Bowman L, Jordan JB.

Health Qual Life Outcomes. 2014 Apr 9;12:48. doi: 10.1186/1477-7525-12-48.

15.

Bisphosphonates for breast cancer.

Pavlakis N, Stockler M.

Cochrane Database Syst Rev. 2002;(1):CD003474. Review. Update in: Cochrane Database Syst Rev. 2005;(3):CD003474.

PMID:
11869664
16.

Health state utilities for non small cell lung cancer.

Nafees B, Stafford M, Gavriel S, Bhalla S, Watkins J.

Health Qual Life Outcomes. 2008 Oct 21;6:84. doi: 10.1186/1477-7525-6-84.

17.

Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial.

Barrett-Lee P, Casbard A, Abraham J, Hood K, Coleman R, Simmonds P, Timmins H, Wheatley D, Grieve R, Griffiths G, Murray N.

Lancet Oncol. 2014 Jan;15(1):114-22. doi: 10.1016/S1470-2045(13)70539-4. Epub 2013 Dec 11. Erratum in: Lancet Oncol. 2014 Feb;15(2):e52-3.

PMID:
24332514
18.

An audit to determine the time taken to administer intravenous bisphosphonate infusions in patients diagnosed with metastatic breast cancer to bone in a hospital setting.

Barrett-Lee P, Bloomfield D, Dougherty L, Harries M, Laing R, Patel H, Walker M.

Curr Med Res Opin. 2007 Jul;23(7):1575-82.

PMID:
17559749
19.

Utility values for advanced soft tissue sarcoma health States from the general public in the United kingdom.

Guest JF, Sladkevicius E, Gough N, Linch M, Grimer R.

Sarcoma. 2013;2013:863056. doi: 10.1155/2013/863056. Epub 2013 Mar 17.

20.

Zoledronic acid: a review of its use in patients with advanced cancer.

Perry CM, Figgitt DP.

Drugs. 2004;64(11):1197-211. Review.

PMID:
15161327

Supplemental Content

Support Center